Showing 851-860 of 5646 results for "".
Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
https://modernod.com/podcasts/eyewire-news-the-podcast/lumithera-ceo-discusses-fda-authorization-for-veleda-for-dry-amd/37059/The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.How to Add Dry Eye Research to Your Clinical Life
https://modernod.com/podcasts/to-the-point/how-to-add-dry-eye-research-to-your-clinical-life/36940/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, are joined by Sathi Maiti, OD, FAAO, who shares her knowledge and experience working on dry eye clinical research. Dr. Maiti offers great advice on what you need to know before seeking out a clinical trial, how to delegate tasks to youOphthalmic Executives Provide Company Updates (Part 1 of 2)
https://modernod.com/podcasts/eyewire-news-the-podcast/ophthalmic-executives-provide-company-updates-part-1-of-2/37057/We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development.Treating Dry Eye at the Molecular Level
https://modernod.com/podcasts/to-the-point/treating-dry-eye-at-the-molecular-level/36939/Jacob Lang, OD, FAAO, shares his knowledge of innovative therapies for dry eye with Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO. He discusses drugs in development that target pathways involved in ocular surface disease, such as reactive aldehyde species inhibitors, transient receTwo Partnerships Formed to Advance Glaucoma Treatments
https://modernod.com/podcasts/eyewire-news-the-podcast/two-partnerships-formed-to-advance-glaucoma-treatments/37051/Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system.83. Myopia: Are We Missing Something?
https://modernod.com/podcasts/four-eyes/83-myopia-are-we-missing-something/37033/Dr. Bilkhu and Dr. Kar dive into an alternative perspective on myopia that challenges the traditional medical approach. While current treatments often focus on myopia as a problem of it’s own, Dr. Bilkhu shares insights on why myopia may actually be a symptom of a deeper problem: near visual stress.Scleral Lenses for Post-Corneal Transplant
https://modernod.com/topics/contact-lenses/scleral-lenses-for-post-corneal-transplant/38855/This lens modality can be a great option for patients with corneal irregularities following surgery.A New Era of ICSC
https://modernod.com/topics/contact-lenses/a-new-era-of-icsc/38850/Find out what this meeting has to offer practitioners at all levels of scleral lens expertise.80. The Role AI Plays in Eye Care and Clinical Trials ft. Dr. George Magrath
https://modernod.com/podcasts/four-eyes/80-the-role-ai-plays-in-eye-care-and-clinical-trials-ft-dr-george-magrath/37030/In this episode, we dive deep into the revolutionary role of artificial intelligence in clinical trials and patient care with Dr. George Magrath, an esteemed ophthalmologist and the CEO of a cutting-edge pharmaceutical company specializing in ophthalmic drug development. Dr. Magrath shares his experPreservatives in Multidose Topical Ophthalmic Drops
https://modernod.com/topics/nutritionpharmaceuticals/preservatives-in-multidose-topical-ophthalmic-drops-1/38812/Recent product recalls emphasize safety concerns.